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Abstract
Background: Maternal immune activation (MIA) during prenatal life is a risk factor for neurodevelopmental disorders
including schizophrenia and autism. Such conditions are associated with alterations in fronto-subcortical circuits, but their
molecular basis is far from clear.
Methodology/Principal Findings: Using two-dimensional differential in-gel electrophoresis (2D-DIGE) and mass
spectrometry, with targeted western blot analyses for confirmation, we investigated the impact of MIA on the prefrontal
and striatal proteome from an established MIA mouse model generated in C57B6 mice, by administering the viral analogue
PolyI:C or saline vehicle (control) intravenously on gestation day (GD) 9. In striatum, 11 proteins were up-regulated and 4
proteins were down-regulated in the PolyI:C mice, while 10 proteins were up-regulated and 7 proteins down-regulated in
prefrontal cortex (PFC). These were proteins involved in the mitogen-activated protein kinase (MAPK) signaling pathway,
oxidation and auto-immune targets, including dual specificity mitogen-activated protein kinase kinase 1 (MEK), eukaryotic
initiation factor (eIF) 4A-II, creatine kinase (CK)-B, L-lactate dehydrogenase (LDH)-B, WD repeat-containing protein and NADH
dehydrogenase in the striatum; and guanine nucleotide-binding protein (G-protein), 14-3-3 protein, alpha-enolase, olfactory
maker protein and heat shock proteins (HSP) 60, and 90-beta in the PFC.
Conclusions/Significance: This data fits with emerging evidence for disruption of critical converging intracellular pathways
involving MAPK pathways in neurodevelopmental conditions and it shows considerable overlap with protein pathways
identified by genetic modeling and clinical post-mortem studies. This has implications for understanding causality and may
offer potential biomarkers and novel treatment targets for neurodevelopmental conditions.
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Introduction
Dysfunction of frontal-subcortical circuits is implicated in
psychiatric conditions with developmental origin, including
schizophrenia [1] and autism [2]. The prefrontal cortex (PFC) is
intimately linked to striatum, pallidum and thalamus via a serial of
frontal-subcortical circuits [3]. The PFC is responsible for
executive function and is heavily involved in social-emotional
processes [4]. Dysfunction of this region results in disorganization
of thoughts and actions, part and parcel of the psychopathology of
schizophrenia. The dopamine rich striatal region interfaces
between the PFC and other brain regions. Therefore, disruption
to prefrontal cortical networks incorporating the striatum are
thought crucial to schizophrenia [5] and also implicated in autism
[2,6]. Consistent with this, fronto-striatal prefrontal circuit
anomalies have been detected in autism [2,6,7] and first episode
schizophrenia prior to medication [1,8,9]; and functional imaging
and sensorimotor gating abnormalities in both conditions are
consistent with fronto-striatal perturbation [6,10,11,12]. However,
the molecular basis of frontal-subcortical dysfunction is uncertain,
therefore, novel treatment targets remain under-exploited.
Proteomics holds potential to undercover pathological mecha-
nisms at the molecular level. Compared to conventional analysis,
two-dimensional differential in-gel electrophoresis (2D-DIGE) has
higherreproducibilityand sensitivitybecause of itsinternal standard
design which minimizes gel-to-gel variation, improves spot-
matching, reduces number of gels needed, and permits quantitative
analysis of small sample amounts [13,14]. Recently, post-mortem
proteomic profiles of different brain regions from patients with
schizophrenia [15,16,17,18,19] have been investigated. The
expression of proteins involved in cell communication, signal
transduction, cellular metabolism, synaptic plasticity, cell growth
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schizophrenia. However drug treatment, chronicity and cause of
death, may confound interpretation and such studies cannot easily
probe causative mechanisms. In contrast, animal models allow
direct examination of aetiological risk factors on brain proteome.
For example, rats with acute methamphetamine-induced behavior-
al sensitization have changes in mitochondrial dysfunction,
oxidative, cytoskeletal, and synaptic proteins, which may hold clues
to the nature of drug-induced psychosis [20,21]. In a schizophrenia
model simulated by neonatal hippocampal lesions in rats, reduced
protein expression in the PFC has been reported, with alterations in
proteins involved in neurotransmitter signaling systems [22].
Maternal immune activation (MIA) during prenatal life increases
risk of development of schizophrenia and related illnesses such as
autism [23,24,25,26]. A substantial body of work has validated MIA in
rodents as a means to simulate neuroanatomical [27,28], neurochem-
ical [29,30], behavioural [31] and gene expression [32] abnormalities
similar to those in schizophrenia, autism and related disorders. In this
study, we adopted an established mouse model of MIA to study the
effects of prenatal immune challenge on protein expression in striatum
and PFC using 2D-DIGE, coupled with western blot analysis of
selected proteins. The MIA model is based on prenatal maternal
treatment with polyriboinosinic- polyribocytidilic acid (PolyI:C).
PolyI:C is a synthetic analogue of virus-specific double-stranded
RNA, which induces a cytokine-associated acute phase response
typically seen following viral infections. As reviewed elsewhere [33,34],
prenatal PolyI:C treatment in rodents induces a variety of behavioral,
cognitive and pharmacological dysfunctions primarily implicated in
schizophrenia and autism. Hence, the prenatal PolyI:C model is highly
suitable for proteomic analyses because of its solid face validity to
schizophrenia and related disorders.
Results
2D-DIGE Processing and Protein Identification
Total soluble brain proteins from CPu and PFC labeled with Cy3 or
Cy5 fluorescent dyes, mixed to form random pairs on each 2D-DIGE
gel, were evenly distributed across the pH 4–7 range and separated
between 10 to 250 kDa on the 12% SDS-PAGE. For CPu, an average
1500 spots were detected in each image by DeCyder DIA module, and
around 1300 spots included for further BVA module analysis after
protein exclusion filters applied (Area,250; Max Peak,100; Max
Volume,10,000; Max Slope.1.75). For PFC, around 1800 spots
were detected and 1300 spots were included for BVA module with
similar protein exclusion filters (Area,250; Max Peak,200; Max
Volume,25,000; Max Slope.1.5). In BVA module, protein spots
detected from each image were automatically matched to the master
image which contained the most protein spots in an experiment and
each protein’s standardized abundance volume was calculated against
the internal standard. The protein fold changes were of a similar order
of magnitude to other studies which have adopted 2D-DIGE
techniques [35]. In addition, protein spots were manually checked to
exclude dust particles and other artifact before further statistical
analysis. Independent Student t-tests compared protein expression
between PolyI:C- treated mice and controls. According to the
significance criteria above, 15 spots in CPu showed significant
alteration in expression (p,0.05; presented .75% images) in
PolyI:C-treated mice compared to the control group. Of these 15
spots, 11 spots showed up-regulation and 4 spots showed down-
regulation. Table 1 lists the 9 proteins identified by mass spectrometry.
In PFC, compared to control group, 18 spots with significant alteration
in expression were detected (p,0.05; presented in .75% images) in
PolyI:C-treated mice,of which 10 spots were detected as up-regulated
and 8 spots down-regulated. Nine protein spots were identified using
mass spectrometry(Table 2), including olfactory marker protein; alpha-
enolase protein; Guanine nucleotide-binding protein (G-protein);
protein kinase C inhibitor protein 1 (KCIP-1) and heat shock proteins.
Figure 1 shows representative expression patterns.
Multivariate Statistical Analysis of Full Proteome Profile
In CPu (Figure 2, A) and PFC (Figure 2, B) respectively, 790
and 524 protein spots present in at least 11 out of 14 (.75%)
images were included in partial least squares-discriminant analyses
Table 1. Differential protein expression in striatum of PolyI:C-treated mice compared to controls.
Classification Spot No.
Fold
change p value Protein name
Protein MW
(kDa)
Protein
PI
Protein
score C.I.%
Pep.
count
NCBInr accession
number
Isomerase CPu356 1.06 down 0.02 WD repeat-containing
protein 1(Actin-interacting
protein 1) (AIP1)
67.0492 6.11 103 99.998 11 gi|12836360
CPu357 1.09 down 0.023 WD repeat-containing
protein 1(Actin-interacting
protein 1) (AIP1)
67.0492 6.11 82 99.798 10 gi|12835959
Transferase CPu717 1.05 down 0.049 Dual specificity mitogen-
activated protein kinase
kinase1 (MAP kinase kinase 1)
(MAPKK 1 or MEK1)
43.7885 6.24 186 100 11 gi|7670399
CPu664 1.12 up 0.0009 Creatine kinase B-type 42.9714 5.4 399 100 14 gi|10946574
CPu650 1.09 up 0.047 Creatine kinase B-type 42.9714 5.4 142 100 8 gi|10946574
CPu659 1.09 up 0.05 Creatine kinase B-type 42.9714 5.4 768 100 21 gi|10946574
Hydrolase/RNA
binding protein
CPu706 1.16 up 0.036 Eukaryotic initiation factor
4A-II
46.6009 5.33 194 100 10 gi|56605748
Oxido-reductase CPu907 1.07 up 0.0045 L-lactate dehydrogenase B
chain (LDH-B) (LDH-H)
36.8341 5.7 82 99.773 7 gi|6678674
CPu1070 1.05 up 0.0024 NADH dehydrogenase
(ubiquinone) iron-sulfur
protein 3
30.3016 6.67 279 100 15 gi|20071222
doi:10.1371/journal.pone.0016638.t001
Brain Proteome Changes after Prenatal Inflammation
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16638(PLS-DA). The PLS-DA showed a clear separation between
groups for both regions (Figure 2).
Western Blot Validation
Differentially expressed proteins detected by 2-D gel and mass
spectrometry were confirmed using western blot analysis of
selected proteins (Figure 3). In PFC, the expression of HSP-90
and 14-3-3 zeta were significantly up-regulated while HSP-60 and
a-enolase were significantly down-regulated in the PolyI:C group
as compared with the control group. In CPu, protein expression of
eIF4A2 was significantly up-regulated. Down-regulation of MEK1
did not reach significance, but a significant down-regulation of
pERK was consistent with lower MEK1 in the PolyI:C group
compared with saline control.
Discussion
Using an epidemiologically motivated neurodevelopmental
animal model of schizophrenia and related disorders, we show
for the first time that prenatal immune challenge in the form of a
viral-like acute phase response triggered in early/middle gestation
(GD9) in mice leads to long-lasting changes in protein expression
at the proteome level. Our quantitative 2D-DIGE techniques
revealed differential expression of proteins in the striatum and
PFC of adult mice prenatally exposed to the viral mimic PolyI:C
relative to adult control mice. More specifically, proteins involved
in the MEK/ERK pathway, oxidation and auto-immune targets
were found to have altered expression in PolyI:C exposed mice,
including dual specificity mitogen-activated protein kinase kinase 1
(MEK1), eukaryotic initiation factor (eIF) 4A-II, creatine kinase
(CK)-B, L-lactate dehydrogenase (LDH)-B, WD repeat-containing
protein and NADH dehydrogenase in the CPu (Table 1); guanine
nucleotide-binding protein (G-protein), 14-3-3 protein zeta/delta
(KCIP-1), alpha-enolase, olfactory maker protein and heat shock
protein (HSP)-60, and 90-beta in the PFC (Table 1). These
proteome wide results were generally confirmed for 8 selected
proteins using western blot (Figure 3) and PLS-DA multivariate
analysis of the full proteome profile clearly separated PolyI:C and
control groups (Figure 2).
In the maternal infection model, cytokine elevation rapidly
triggers cellular defense programs [36]. Smith and Patterson
concluded several cytokine signaling pathways, such as NF-kB
and/or JAK/STAT, are involved in the modulation of cell
proliferation, differentiation and migration during prenatal brain
development. Activation of JAK/STAT pathway is particularly
important in neuronal regeneration, embryonic development [37],
neurogensis and gliogensis [38]. Pro-inflammatory cytokines have
been shown to inhibit cortical neuron dendrite development in
embryonic day 18 rat cortical cultures [39]. In our study, when
triggered by pro-inflammatory cytokines, the intracellular signal
transduction networks modified downstream of JAK/STAT,
included the mitogen-activated protein kinase (MAPK) cascade
which contains Ras/Raf, MEK, ERK. Confirmatory western blot
analysis indicated lower level of phosphorylated ERK (pERK) was
indeed a consequence of prenatal cytokine exposure, probably due
to down-regulation of MEK. This finding is consistent with cell-
culture study showing viral infection interferes with ERK1/2
phosphorylation in hippocampal neurones [40].
Post-mortem studies in patients of schizophrenia suggest the
MAPK pathway is disrupted [41] with decreased MAPK1 gene
expression reported in schizophrenia post-mortem samples [42].
In addition, preclinical investigation suggests the MAPK pathway
is modified by anti-psychotic drug treatment [43,44]. Chronic
treatment with olanzapine activates the MAPK pathway leading to
phosphorylation of MEK1/2 and ERK1/2 [43], suggesting that
the lower MEK1 observed in our study may constitute a potential
pharmacological target. Consistent with this, epigenetic regulation
of MEK1 via methylation of an upstream CpG island has been
reported to correlate with antipsychotic use in schizophrenia [44].
In addition, in both the knock-out mouse model of Fragile X and
peripheral blood lymphocytes from individuals with fragile X, a
condition associated with autism, Berry-Kravis et al [45] showed
delayed phosphorylation of ERK, partly overlapping our obser-
vation that PolyI:C mice have lower MEK and pERK.
Activation of STAT3 trigged by cytokines may be rapidly
inhibited by MEK-ERK negative regulation [46]. Our finding
that prenatal inflammation down-regulates expression of MEK
and pERK in the CPu region suggests the prenatal PolyI:C
Table 2. Differential protein expression in prefrontal cortex of PolyI:C-treated mice compared to controls.
Chaperone PFC324 1.1 up 0.028 Heat shock protein HSP 90-beta 83.5712 4.97 466 100 29 gi|123681
PFC522 1.15 down 0.003 Heat shock protein HSP60 60.8849 5.38 163 100 8 gi|51452
Lyase PFC731 1.11 down 0.013 Alpha-enolase (2-phospho-D-
glycerate hydro-lyase)
47.6345 6.63 288 100 17 gi|6679651
PFC739 1.15 down 0.013 Alpha-enolase (2-phospho-D-
glycerate hydro-lyase)
(Non-neural enolase)
47.4533 6.37 118 100 11 gi|70794816
Hydrolase PFC1061 1.07 down 0.029 Platelet-activating factor
acetylhydrolase IB subunit
25.7242 5.57 196 100 4 gi|33440467
Signaling protein PFC942 1.07 up 0.023 Guanine nucleotide-binding
protein G(I)/G(S)/G(T) subunit
beta-1
38.1513 5.6 470 100 13 gi|6680045
PFC1069 1.29 up 0.028 14-3-3 protein zeta/delta
(Protein kinase C inhibitor
protein 1) (KCIP-1)
27.9248 4.73 104 99.999 8 gi|6756041
PFC1070 1.2 up 0.059 14-3-3 protein zeta/delta
(Protein kinase C inhibitor
protein 1) (KCIP-1)
28.1829 4.77 183 100 12 gi|3065925
PFC1176 2.95 up 0.038 Olfactory marker protein 18.8547 5 128 100 7 gi|6754936
doi:10.1371/journal.pone.0016638.t002
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widespread impact upon multiple cellular processes. The MAPK
cascade is a vital cellular pathway for neuronal differentiation and
function [47]. The 14-3-3 protein is key intracellular binding
protein and one of its actions is to facilitate RAF activation of
MEK [48]. Heat shock protein (HSP)-90 is also required to
activate the RAF signaling cascade [49]. Our results showing both
14-3-3 and HSP-90 proteins were up-regulated in PolyI:C exposed
offspring might indicate a facilitation of RAF to compensate for
lower expression of MEK. Moreover, activation of HSP-90
appears to be coupled to the activation of IL6/STAT3 [50],
and is over expressed in patients with schizophrenia [51], while
14-3-3 proteins were have been reported to be elevated in nucleus
accumbens of isolation reared rats [52], and in the posterior
hippocampus of post-mortem tissue from patients with schizo-
phrenia [17].
Figure 1. Differential expression patterns of proteins-of-interest and their abundances relative to the internal standard in the BVA
module.
doi:10.1371/journal.pone.0016638.g001
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of ErbB receptor netweork by ligands such as neuregulin 1 (nrg1).
ERK phosphorylation is an end result of ErbB activation. In
addition to possible disruption of MAPK signaling in schizophre-
nia and related conditions discussed above, nrg1 is a susceptibility
gene for schizophrenia and expression of ErbB3 protein is
defective in schizophrenia [53]. Our finding that a key inhibitory
regulator of neuregulin-ErbB is up-regulated in the MIA model
along with a down-regulation of MAPK signaling is therefore
compelling, suggesting the same pathways are targeted by genetic
and environmental perturbations relevant to neurodevelopmental
conditions.
There is considerable cross-talk between MAPK pathway and
others such as PI3K/PTEN, mTOR and fragile X mental
retardation protein (FMRP) pathways [54]. PTEN mutations are
associated with autism [55,56], as are tuberose sclerosis and fragile
X, which disrupt mTOR signaling. These pathways modulate
protein translation via the eIF4 family proteins. In PolyI:C
exposed offspring the eukaryotic initiation factor (eIF) 4A-II
protein was up-regulated in the CPu. Recently novel association of
the eIF4E protein component of this family with autism was
reported [57]. Thus disruption of a number of critical converging
pathways including MAPK, PTEN, mTOR and FMRP appears
important in neurodevelopmental conditions, either as a conse-
quence of genetic or environmental risk factors during prenatal life
[58]. GSK3b interfaces between these pathways [59,60], inhibited
by MEK and mGLUR signaling [61] and increased by PTEN
inhibition of PI3K/AKT. Lastly, in addition to facilitating Raf,
protein 14-3-3, up-regulated in PolyI:C exposed mice regulates
GSK3b interactions including phosphorylation of Tau [62]. These
multiple clues pointing to GSK3b may be important to follow up
in future studies because GSK3b inhibitors, such as Lithium, offer
potential therapeutic options [61,63].
Down-regulation of heat shock protein (HSP)-60 detected in
PFC of PolyI:C exposed offspring, agrees with other schizophre-
nia-like models [52,64]. In Roncada’s study [52], isolation-reared
rats showed significant pre-pulse inhibition (PPI) deficits correlated
with the level of HSP-60 decrease. The MIA model has also
reliably been shown to precipitate PPI impairment [28,31]. HSP-
60 is a proposed auto-immune target in schizophrenia [65,66].
Similarly, alpha-enolase (NNE), significantly down-regulated in
PolyI:C exposed offspring, is considered an auto-antigen [67]. In
the MK801 rat model, NNE increased in the thalamus of MK801
short-term treated rats, but decreased with long-term treatment
[64]. Combined with the evidence of lower HSP-60, which echoes
reduction in liver proteome of patients with schizophrenia [65],
our results raise the issue of whether the immune system is
chronically affected following activation in fetal life. Certainly
immune mechanisms have been suggested to explain glutamergic
and dopaminergic disregulation characteristic of schizophrenia
[68], and autism is accompanied by persistent immunological
anomalies [69]. Proteomic and transcriptome studies in schizo-
phrenia are also consistent with dysregulation of immune
pathways [42,70].
Other proteins altered in PolyI:C mice included creatine kinase
(CK), actin-interacting proteins, L-lactate dehydrogenase proteins,
NADH dehydrogenase iron-sulfur (Fe-S) proteins and WD repeat
protein 1. The direction of change identified here is often, but not
always, similar to that reported in analyses of schizophrenia post-
mortem proteome. For example, NADH dehydrogenase was up-
regulated here and has previously been reported as upregulated in
schizophrenia posterior hippocampal post-mortem samples but
reduced in anterior hippocampus [17]. CK type B was up-
regulated here similar to findings in schizophrenia post-mortem
tissue [16]. Moreover, CK isoforms are associated with the 14-3-3
protein complex [71,72] so, that both are up regulated within this
model is internally consistent. In contrast, WD repeat protein 1
has been reported as up-regulated in schizophrenia post-mortem
tissue but was down-regulated in our model [70]. Possible reasons
for divergent findings are many-fold, but may include contribution
from medication exposure and illness progression in the clinical
samples.
Our study has a number of limitations. A standard global scale
proteomic analysis was applied to brain homogenate lysates.
However, this approach does not fully sample different intracel-
lular organelles in the brain. A further limitation was the modest
rate of successful protein identification in mass spectrometric
analysis, particularly in PFC. This false negative error may be
because the regional homogenate was insensitive to low protein
abundance. Given that the gels are loaded with a fixed protein
quantity, more proteins separated, theoretically means lower
concentrations of individual proteins. One solution is the use of
subcellular fractions such as mitochondria, nuclear and plasma
membrane which can further separate from brain lysates with
chemical or physical fractionation techniques. Fractionation
techniques, though challenging, will form good future partnership
with proteomics [22].
In conclusion, prenatal immune challenge causes changes across
the fronto-striatal proteome echoing findings from diverse studies
on post-mortem tissue, genetic analyses and animal model systems.
Specifically, our data fits with evidence for disruption of critical
proteins within converging intracellular pathways involving
MAPK in neurodevelopmental conditions. Further investigation
of protein pathways in this and other related models may hold
promise for further identification of disease biomarkers and novel
treatment targets.
Figure 3. Western blot analysis of the differentially expressed
target proteins in PolyI:C and control group. (A) Gel image of
protein products in the control and PolyI:C group. (B) The relative
expression of the target proteins/b-actin protein. Columns show mean
6 SEM (n=8 for PFC and n=6 for CPu). *p,0.05 and **p,0.005 vs.
corresponding control group.
doi:10.1371/journal.pone.0016638.g003
Figure 2. PolyI:C mice group was differentiated from controls using PLS-DA analysis of the whole CPu (A) and PFC (B) proteome.
M, male; F, female.
doi:10.1371/journal.pone.0016638.g002
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Animals and Sample Purification
C57BL6/J mice were used for the experiment. All procedures
described in the present study had been previously approved by
the Cantonal Veterinarian’s Office of Zurich (permit number 28-
2009) and are in agreement with the principles of laboratory
animal care in the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health Publication No. 86-23, revised
1985). All efforts were made to minimize the number of animals
used and their suffering. After local ethic review board approval,
and following previously published protocol [27,28,31], 5mg/kg
PolyI:C (potassium salt dissolved in saline, Sigma Aldrich) was
administered in an injection volume of 5ml/kg to pregnant
C57BL6/J mice on gestation day (GD) 9 via the tail vein. Control
animals received 5ml/kg saline via tail vein on GD9. The resulting
offspring were weaned and sexed at postnatal day (PND) 21.
Littermates of the same sex were caged separately, three to four
per cage. At adult age (PND 70), 7 mice (4 male and 3 female
offspring) from each prenatal treatment group (saline and PolyI:C)
were randomly selected from different litters. Hence, a total of 14
mice (7 control, 7 PolyI:C) were included in the 2D-DIGE
analyses. Animals were sacrificed by decapitation and brains
dissected, immediately frozen and stored at 280uC. Brain tissue
from striatum (CPu) and PFC of saline- and PolyI:C-treated mice
were individually thawed and homogenized in 2D-DIGE lysis
buffer (30mM Tris, 7M Urea, 2M Thiourea, 4% CHAPS, pH 8.5;
at 4uC) for 30 seconds, then centrifuged at 15,0006g for 15 min to
remove cell debris. Supernatant was collected and quantified with
2-D Quant Kit (Amersham Biosciences) before loading gels for
2D-DIGE separation.
2D-DIGE Analysis and Protein Identification by Mass
Spectrometry
2D-DIGE analyses of CPu and PFC samples were conducted
independently. The procedure has been described previously [35].
Briefly, for each region, 50mg of protein was randomly labeled with
400 pmol of CyDye DIGE Fluor minimal dye (GE Healthcare),
Cy3 or Cy5, and the pooled internal standard with Cy2. Labeled
samples were randomly mixed and assigned to seven gels, each of
which contained Cy2-, Cy3- and Cy5-labeled samples, respectively
[73]. Mixed pre-labeled samples were loaded to the 18cm, pH 4–
7, IPG DryStrips (Bio-Rad) for first dimensional isoelectric
focusing (IEF) separation (Bio-Rad IEF system), and secondary
dimensional separation by 12% SDS-PAGE (Bio-Rad vertical
system). Fluorescent images were obtained by Typhoon
TM 9410
scanner (GE Healthcare). For each region, a total of 14 images
from 7 gels with good separation quality were analyzed using
DeCyder software version 6.5 containing Differential In-gel
Analysis (DIA) module and Biological Variation Analysis (BVA)
module (Amersham Biosciences). The abundance of protein spots
was intra- and inter- gel normalized according to the internal
standard. Statistical analysis of different protein spot intensity
between groups was performed using independent Student’s t-tests
run on the normalized protein abundance in DeCyder software.
Protein spots with p-value less than 0.05 and present in at least 11
out of 14 (.75%) images [65] were considered significant. Spots of
interest were picked from the silver-stained 2D-DIGE gels and
followed by in-gel trypsin digestion and peptide extraction [35] for
protein identification by tandem mass spectrometry analysis using
ABI 4800 MALDI TOF/TOF
TM MS Analyzer (Applied Biosys-
tems, Foster City, CA, USA). The combined peptide mass
fingerprinting (PMF) and MS/MS peptide fragmentation data
were submitted to the NCBInr database and SwissProt database
using the software GPS Explorer, version 3.6 (Applied Biosystems)
and in-house MASCOT version 2.2 (Matrix Science) with
parameters: one missed cleavage allowed; initial mass tolerance
of 75ppm; fixed modification, carbamidomethyl (Cys); variable
modification, oxidation (Met); precursor tolerance of 60.2 Da.
For all significant protein identifications, both protein and total ion
scores were above or equal to C.I. 95% [35].
Multivariate Statistical Analysis of Full Proteome Profile
Multivariate analysis using partial least squares-discriminant
analysis (PLS-DA) was performed to examine whether PolyI:C
groups could be separated from control groups on the basis of the
full proteome profile [65,74]. Data was imported into SIMCA 9.0
software (Umetrics, Umea, Sweden) as previously described [38].
Only protein spots present in at least 11 out of 14 (.75%) images
were included in the analyses [65,74].
Western Blot Validation
Brain tissues from CPu (n=8) and PFC (n=6) of equal numbers
of male and female saline and PolyI:C-treated mice were
homogenized at 4uC in lysis buffer (1:5, wt/vol) containing
1 mM EDTA and 20 mM phenylmethylsulphonyl fluoride. The
proteins from resultant supernatant were determined (Bio-Rad
Protein Assay) for Sodium Dodecyl-sulphate Polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins (20 mg/lane) were subjected
to electrophoresis on a 12% (wt/vol) polyacrylamide gel in SDS,
and gels subsequently processed for electroblotting to polyvinyli-
dene difluoride (PVDF) membranes. The blotted PVDF mem-
branes were saturated with 5% (wt/vol) of skimmed milk in Tris
Buffer Saline, pH 7.4 and 0.1% (vol/vol) of Tween 20 for 1 h at
room temperature. The membranes were sequentially incubated
with primary antibodies to the following proteins: HSP90 (rabbit
polyclonal IgG antibody, 1:2000 dilution, Cat # ab13495, Abcam,
MA, USA), HSP60 (rabbit polyclonal IgG antibody, 1:2000
dilution, Cat # ab68416, Abcam, MA, USA), a-enolase (rabbit
polyclonal IgG antibody, 1:5000 dilution, Cat # ab49343, Abcam,
MA, USA), 14-3-3 zeta (rabbit polyclonal IgG antibody, 1:1000
dilution, Cat # ab51129, Abcam, MA, USA), eIF4A2 (rabbit
polyclonal IgG antibody, 1:1000 dilution, Cat # ab31218, Abcam,
MA, USA), MEK1 (rabbit polyclonal IgG antibody, 1:500
dilution, Cat # ab59294, Abcam, MA, USA), ERK (rabbit
polyclonal IgG antibody, 1:1000 dilution, Cat # sc94, Santa Cruz
Biotechnology, CA, USA) and pERK (mouse monoclonal IgG
antibody, 1:500 dilution, Cat # sc7383, Santa Cruz Biotechnol-
ogy, CA, USA), overnight at 4uC following by a peroxidase-
labeled anti-mouse/rabbit IgG (1:2000 dilution, Boehringer
Mannheim, Germany) for 1 h at room temperature. After
thorough washing, the positive bands were revealed using ECL
western blotting detection reagents and autoradiography film
(Amersham, Biosciences, UK). The intensities of the bands were
quantified using IMAGE QUANT software (Molecular Dynamics,
USA).
Acknowledgments
Thanks to Prof R Quiron and Dr FGG Vercauteren for guidance in the
early stages; Dr Agnes Wong and Genome Research Centre staff,
University of Hong Kong, for dedicated service.
Author Contributions
Conceived and designed the experiments: MYD UM JF SEC PS YW
GMM. Performed the experiments: MYD SL QL RW LL. Analyzed the
data: MYD SL GMM. Contributed reagents/materials/analysis tools: SEC
PS YW GMM. Wrote the paper: MYD SL UM GMM.
Brain Proteome Changes after Prenatal Inflammation
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16638References
1. Chua SE, Cheung C, Cheung V, Tsang JT, Chen EY, et al. (2007) Cerebral
grey, white matter and csf in never-medicated, first-episode schizophrenia.
Schizophr Res 89: 12–21.
2. McAlonan GM, Cheung V, Cheung C, Suckling J, Lam GY, et al. (2005)
Mapping the brain in autism. A voxel-based MRI study of volumetric differences
and intercorrelations in autism. Brain 128: 268–276.
3. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of
functionally segregated circuits linking basal ganglia and cortex. Annu Rev
Neurosci 9: 357–381.
4. Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function.
Annu Rev Neurosci 24: 167–202.
5. Weinberger DR, Berman KF, Zec RF (1986) Physiologic dysfunction of
dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow
evidence. Arch Gen Psychiatry 43: 114–124.
6. McAlonan GM, Daly E, Kumari V, Critchley HD, van Amelsvoort T, et al.
(2002) Brain anatomy and sensorimotor gating in Asperger’s syndrome. Brain
125: 1594–1606.
7. Cheung C, Chua SE, Cheung V, Khong PL, Tai KS, et al. (2009) White matter
fractional anisotrophy differences and correlates of diagnostic symptoms in
autism. J Child Psychol Psychiatry 50: 1102–1112.
8. Cheung V, Cheung C, McAlonan GM, Deng Y, Wong JG, et al. (2008) A
diffusion tensor imaging study of structural dysconnectivity in never-medicated,
first-episode schizophrenia. Psychol Med 38: 877–885.
9. Leung M, Cheung C, Yu K, Yip B, Sham P, et al. (2009) Gray Matter in First-
Episode Schizophrenia Before and After Antipsychotic Drug Treatment.
Anatomical Likelihood Estimation Meta-analyses With Sample Size Weighting.
Schizophr Bull.
10. Hazlett EA, Buchsbaum MS, Zhang J, Newmark RE, Glanton CF, et al. (2008)
Frontal-striatal-thalamic mediodorsal nucleus dysfunction in schizophrenia-
spectrum patients during sensorimotor gating. Neuroimage 42: 1164–1177.
11. Just MA, Cherkassky VL, Keller TA, Kana RK, Minshew NJ (2007) Functional
and anatomical cortical underconnectivity in autism: evidence from an FMRI
study of an executive function task and corpus callosum morphometry. Cereb
Cortex 17: 951–961.
12. Kumari V, Gray JA, Geyer MA, ffytche D, Soni W, et al. (2003) Neural
correlates of tactile prepulse inhibition: a functional MRI study in normal and
schizophrenic subjects. Psychiatry Res 122: 99–113.
13. Tannu NS, Hemby SE (2006) Two-dimensional fluorescence difference gel
electrophoresis for comparative proteomics profiling. Nat Protoc 1: 1732–1742.
14. Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single
gel method for detecting changes in protein extracts. Electrophoresis 18:
2071–2077.
15. Behan A, Byrne C, Dunn MJ, Cagney G, Cotter DR (2008) Proteomic analysis
of membrane microdomain-associated proteins in the dorsolateral prefrontal
cortex in schizophrenia and bipolar disorder reveals alterations in LAMP,
STXBP1 and BASP1 protein expression. Mol Psychiatry.
16. Clark D, Dedova I, Cordwell S, Matsumoto I (2006) A proteome analysis of the
anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11:
459–470, 423.
17. Nesvaderani M, Matsumoto I, Sivagnanasundaram S (2009) Anterior hippo-
campus in schizophrenia pathogenesis: molecular evidence from a proteome
study. Aust N Z J Psychiatry 43: 310–322.
18. Novikova SI, He F, Cutrufello NJ, Lidow MS (2006) Identification of protein
biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal
cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-
TOF-PSD-MS analysis. Neurobiol Dis 23: 61–76.
19. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004)
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain
metabolism and oxidative stress. Mol Psychiatry 9: 684–697, 643.
20. Iwazaki T, McGregor IS, Matsumoto I (2006) Protein expression profile in the
striatum of acute methamphetamine-treated rats. Brain Res 1097: 19–25.
21. Iwazaki T, McGregor IS, Matsumoto I (2007) Protein expression profile in the
striatum of rats with methamphetamine-induced behavioral sensitization.
Proteomics 7: 1131–1139.
22. Vercauteren FG, Flores G, Ma W, Chabot JG, Geenen L, et al. (2007) An
organelle proteomic method to study neurotransmission-related proteins, applied
to a neurodevelopmental model of schizophrenia. Proteomics 7: 3569–3579.
23. Brown AS, Susser ES (2002) In utero infection and adult schizophrenia. Ment
Retard Dev Disabil Res Rev 8: 51–57.
24. Chess S, Fernandez P, Korn S (1978) Behavioral consequences of congenital
rubella. J Pediatr 93: 699–703.
25. Sham PC, O’Callaghan E, Takei N, Murray GK, Hare EH, et al. (1992)
Schizophrenia following pre-natal exposure to influenza epidemics between
1939 and 1960. Br J Psychiatry 160: 461–466.
26. Takei N, Mortensen PB, Klaening U, Murray RM, Sham PC, et al. (1996)
Relationship between in utero exposure to influenza epidemics and risk of
schizophrenia in Denmark. Biol Psychiatry 40: 817–824.
27. Li Q, Cheung C, Wei R, Cheung V, Hui ES, et al. (2010) Voxel-based analysis
of postnatal white matter microstructure in mice exposed to immune challenge
in early or late pregnancy. Neuroimage 52: 1–8.
28. Li Q, Cheung C, Wei R, Hui ES, Feldon J, et al. (2009) Prenatal immune
challenge is an environmental risk factor for brain and behavior change relevant
to schizophrenia: evidence from MRI in a mouse model. PLoS ONE 4: e6354.
29. Shi L, Fatemi SH, Sidwell RW, Patterson PH (2003) Maternal influenza
infection causes marked behavioral and pharmacological changes in the
offspring. J Neurosci 23: 297–302.
30. Winter C, Djodari-Irani A, Sohr R, Morgenstern R, Feldon J, et al. (2009)
Prenatal immune activation leads to multiple changes in basal neurotransmitter
levels in the adult brain: implications for brain disorders of neurodevelopmental
origin such as schizophrenia. Int J Neuropsychopharmacol 12: 513–524.
31. Meyer U, Feldon J, Schedlowski M, Yee BK (2006) Immunological stress at the
maternal-foetal interface: a link between neurodevelopment and adult
psychopathology. Brain Behav Immun 20: 378–388.
32. Fatemi SH, Pearce DA, Brooks AI, Sidwell RW (2005) Prenatal viral infection in
mouse causes differential expression of genes in brains of mouse progeny: a
potential animal model for schizophrenia and autism. Synapse 57: 91–99.
33. Meyer U, Feldon J (2010) Epidemiology-driven neurodevelopmental animal
models of schizophrenia. Prog Neurobiol 90: 285–326.
34. Meyer U, Feldon J, Fatemi SH (2009) In-vivo rodent models for the
experimental investigation of prenatal immune activation effects in neurodevel-
opmental brain disorders. Neurosci Biobehav Rev.
35. Wang Y, Lam KS, Lam JB, Lam MC, Leung PT, et al. (2007) Overexpression of
angiopoietin-like protein 4 alters mitochondria activities and modulates
methionine metabolic cycle in the liver tissues of db/db diabetic mice. Mol
Endocrinol 21: 972–986.
36. Smith SEP, Patterson PH (2008) Alteration of Neurodevelopment and behavior
by Maternal Immune ActivationAlteration of Neurodevelopment and behavior
by Maternal Immune ActivationAlteration of Neurodevelopment and Behavior
by Maternal Immune Activation. In: Siegel A, Zalcman SS, eds. The
Neuroimmunological Basis of Behavior and Mental Disorders: Springer US.
pp 111–130.
37. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, et al.
(2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
Biochem J 374: 1–20.
38. Zhao B, Schwartz JP (1998) Involvement of cytokines in normal CNS
development and neurological diseases: recent progress and perspectives.
J Neurosci Res 52: 7–16.
39. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH (2001) Cytokine
effects on cortical neuron MAP-2 immunoreactivity: implications for schizo-
phrenia. Biol Psychiatry 50: 743–749.
40. Hans A, Bajramovic JJ, Syan S, Perret E, Dunia I, et al. (2004) Persistent,
noncytolytic infection of neurons by Borna disease virus interferes with ERK 1/2
signaling and abrogates BDNF-induced synaptogenesis. FASEB J 18: 863–865.
41. Kyosseva SV, Elbein AD, Griffin WS, Mrak RE, Lyon M, et al. (1999) Mitogen-
activated protein kinases in schizophrenia. Biol Psychiatry 46: 689–696.
42. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K (2007) Molecular evidence for
increased expression of genes related to immune and chaperone function in the
prefrontal cortex in schizophrenia. Biol Psychiatry 62: 711–721.
43. Fumagalli F, Frasca A, Sparta M, Drago F, Racagni G, et al. (2006) Long-term
exposure to the atypical antipsychotic olanzapine differently up-regulates
extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular
compartments of rat prefrontal cortex. Mol Pharmacol 69: 1366–1372.
44. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, et al. (2008)
Epigenomic profiling reveals DNA-methylation changes associated with major
psychosis. Am J Hum Genet 82: 696–711.
45. Berry-Kravis E, Potanos K (2004) Psychopharmacology in fragile X syndrome–
present and future. Ment Retard Dev Disabil Res Rev 10: 42–48.
46. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB (1998) Rapid inhibition of
interleukin-6 signaling and Stat3 activation mediated by mitogen-activated
protein kinases. Proc Natl Acad Sci U S A 95: 11107–11112.
47. Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/
ERK pathway by protein interactions. Biochem J 351 Pt 2: 289–305.
48. Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat
Rev Neurosci 4: 752–762.
49. Pearl LH (2005) Hsp90 and Cdc37 – a chaperone cancer conspiracy. Curr Opin
Genet Dev 15: 55–61.
50. Stephanou A, Isenberg DA, Akira S, Kishimoto T, Latchman DS (1998) The
nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of
transcription-3 (STAT-3) signalling pathways co-operate to mediate the
activation of the hsp90beta gene by interleukin-6 but have opposite effects on
its inducibility by heat shock. Biochem J 330 (Pt 1): 189–195.
51. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, et al. (2001) Identification of
antibodies to heat shock proteins 90 kDa and 70 kDa in patients with
schizophrenia. Schizophr Res 52: 127–135.
52. Roncada P, Bortolato M, Frau R, Saba P, Flore G, et al. (2009) Gating deficits in
isolation-reared rats are correlated with alterations in protein expression in
nucleus accumbens. J Neurochem 108: 611–620.
53. Corfas G, Roy K, Buxbaum JD (2004) Neuregulin 1-erbB signaling and the
molecular/cellular basis of schizophrenia. Nat Neurosci 7: 575–580.
54. Bronchud MH (2008) Principles of molecular oncology. Totowa, N.J.: Humana
Press.xix, 418 p.
Brain Proteome Changes after Prenatal Inflammation
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e1663855. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, et al. (2005)
Subset of individuals with autism spectrum disorders and extreme macrocephaly
associated with germline PTEN tumour suppressor gene mutations. J Med
Genet 42: 318–321.
56. Varga EA, Pastore M, Prior T, Herman GE, McBride KL (2009) The
prevalence of PTEN mutations in a clinical pediatric cohort with autism
spectrum disorders, developmental delay, and macrocephaly. Genet Med 11:
111–117.
57. Neves-Pereira M, Muller B, Massie D, Williams JH, O’Brien PC, et al. (2009)
Deregulation of EIF4E: a novel mechanism for autism. J Med Genet.
58. Moy SS, Nadler JJ (2008) Advances in behavioral genetics: mouse models of
autism. Mol Psychiatry 13: 4–26.
59. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, et al. (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/
STAT pathways to leukemia. Leukemia 22: 686–707.
60. To MD, Perez-Losada J, Mao JH, Balmain A (2005) Crosstalk between Pten and
Ras signaling pathways in tumor development. Cell Cycle 4: 1185–1188.
61. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, et al. (2009) Elevated
glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator
with evidence for treatment potential. Neuropharmacology 56: 463–472.
62. Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han D, et al. (2003) 14-
3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-
associated tau phosphorylation complex. J Biol Chem 278: 12722–12728.
63. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, et al. (2010) Lithium
ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model
of fragile X syndrome. Biochem Pharmacol 79: 632–646.
64. Paulson L, Martin P, Nilsson CL, Ljung E, Westman-Brinkmalm A, et al. (2004)
Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics
4: 819–825.
65. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, et al.
(2007) 2-D DIGE analysis of liver and red blood cells provides further evidence
for oxidative stress in schizophrenia. J Proteome Res 6: 141–149.
66. Wang XF, Wang D, Zhu W, Delrahim KK, Dolnak D, et al. (2003) Studies
characterizing 60 kda autoantibodies in subjects with schizophrenia. Biol
Psychiatry 53: 361–375.
67. Terrier B, Degand N, Guilpain P, Servettaz A, Guillevin L, et al. (2007) Alpha-
enolase: a target of antibodies in infectious and autoimmune diseases.
Autoimmun Rev 6: 176–182.
68. Muller N, Schwarz M (2006) Schizophrenia as an inflammation-mediated
dysbalance of glutamatergic neurotransmission. Neurotox Res 10: 131–148.
69. Pardo CA, Vargas DL, Zimmerman AW (2005) Immunity, neuroglia and
neuroinflammation in autism. Int Rev Psychiatry 17: 485–495.
70. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, et al.
(2009) Prefrontal cortex shotgun proteome analysis reveals altered calcium
homeostasis and immune system imbalance in schizophrenia. Eur Arch
Psychiatry Clin Neurosci 259: 151–163.
71. Fountoulakis M, Tsangaris GT, Maris A, Lubec G (2005) The rat brain hippocampus
proteome. J Chromatogr B Analyt Technol Biomed Life Sci 819: 115–129.
72. Suginta W, Karoulias N, Aitken A, Ashley RH (2001) Chloride intracellular
channel protein CLIC4 (p64H1) binds directly to brain dynamin I in a complex
containing actin, tubulin and 14-3-3 isoforms. Biochem J 359: 55–64.
73. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, et al. (2003) A novel
experimental design for comparative two-dimensional gel analysis: two-
dimensional difference gel electrophoresis incorporating a pooled internal
standard. Proteomics 3: 36–44.
74. Karp NA, Griffin JL, Lilley KS (2005) Application of partial least squares
discriminant analysis to two-dimensional difference gel studies in expression
proteomics. Proteomics 5: 81–90.
Brain Proteome Changes after Prenatal Inflammation
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16638